Gilead Sciences Sees Unusually Large Options Volume (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) saw some unusual options trading on Tuesday. Investors bought 16,499 put options on the stock. This represents an increase of approximately 107% compared to the typical daily volume of 7,952 put options.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Bank of America boosted their target price on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Truist Financial lifted their price objective on Gilead Sciences from $158.00 to $181.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Royal Bank Of Canada lifted their price objective on Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a research note on Friday, October 30th. Zacks Research cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. Finally, Needham & Company LLC set a $175.00 target price on Gilead Sciences in a research note on Friday. Twenty-three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $169.74.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain broadly upbeat, with several recent price-target increases, including targets as high as $200. Coverage cites Gilead’s recent execution, HIV franchise and pipeline; a separate estimate of fair value also moved higher. Gilead price target raised to $200 Gilead fair-value estimate
• Positive Sentiment: Gilead plans to present results from more than 50 studies, including late-breaking clinical data and real-world evidence, at HIV Glasgow 2026 on November 8–11. The updates could offer pipeline and franchise catalysts. Gilead HIV Glasgow presentation
• Positive Sentiment: BioNTech said it advanced a planned Phase 3 trial, pending regulatory approval, combining its candidate pumitamig with Gilead’s cancer drug Trodelvy in triple-negative breast cancer. This represents potential progress for Gilead’s oncology collaboration, though the study remains subject to approval. BioNTech quarterly results and update
• Negative Sentiment: Investors bought 16,499 GILD put options, about 107% above typical volume. The jump may signal increased hedging or bearish positioning, although options activity alone does not establish a market view.
• Negative Sentiment: CEO Daniel O’Day sold a combined 30,881 shares in two recent transactions. Both sales were made under a prearranged Rule 10b5-1 plan, which may temper their significance, but insider selling can still be viewed cautiously by investors. CEO share sale details

Gilead Sciences Price Performance

NASDAQ:GILD opened at $167.47 on Wednesday. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 0.95. Gilead Sciences has a one year low of $116.88 and a one year high of $175.65. The company has a fifty day moving average price of $151.77 and a 200 day moving average price of $140.25. The stock has a market cap of $207.72 billion, a P/E ratio of -53.00 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.36. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period last year, the business posted $2.47 EPS. Analysts anticipate that Gilead Sciences will post -1.03 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.

Insider Buying and Selling

In other news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the sale, the insider owned 118,234 shares of the company’s stock, valued at $16,273,727.76. The trade was a 19.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 126,881 shares of company stock valued at $19,252,455. 0.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors have recently added to or reduced their stakes in GILD. BlackRock Inc. acquired a new stake in shares of Gilead Sciences in the second quarter valued at $15,393,785,000. Legal & General Group Plc bought a new position in shares of Gilead Sciences in the second quarter valued at about $1,316,606,000. Deutsche Bank AG acquired a new position in Gilead Sciences during the 2nd quarter worth about $918,387,000. Jupiter Topco LLC acquired a new position in Gilead Sciences during the 2nd quarter worth about $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Gilead Sciences during the 2nd quarter worth about $398,905,000. 83.67% of the stock is owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.